Table 2.

MicroRNA signature in various lymphoid malignancies. The table shows microRNAs that have been detected at higher or lower levels in lymphoid malignancies according to data in the literature. More detailed description is found in Sections 3 and 4. It should be emphasized that the table presents microRNAs that are frequently dysregulated, and the microRNA expression pattern may vary during disease progression and depends on the ontogeny and tumor grade. Also, there are variabilities between the different studies which may be due to generalized classification or more specific classification of the given malignancy. Also, the reference gene and cell type used as control may affect the interpretation of microRNA profiling. MicroRNAs that can affect or are related to GC signaling and/or GC-induced apoptosis are highlighted in bold.

Cancer type	Increased expression	Decreased expression	References
ALL	miR-17~92 cluster, miR-26a, miR-29a/b/c, miR-125b-1*, miR-128a, miR-128b, miR-146a, miR-204, miR-218, miR-331, miR-181a, miR-181b, miR-181c, miR-142-3P, miR-142, miR-150, miR-155, miR-193a, miR-196b, miR-30e-5p, miR-34b, miR-365, miR-582, miR-708, miR-223*	let-7b, miR-223*, miR-100, miR-125b*, miR-151, miR-99a, miR-124a	[253, 557–562]
CLL	miR-21, miR-23b, miR-24-1, miR-146a, miR-150*, miR-155, miR-106b, miR-195, miR-221*, miR-222*, miR-181a/b*, miR-19a, miR-20a, miR-106b, miR-142*, miR-29a/c*, miR-130, miR-26a, miR-197, miR-342, miR-483, miR-595	miR-15a, miR-16-1, miR-29*, miR-34a, miR-143, miR-45, miR-30d, let-7a, miR-181a/b*, miR-223, miR-92, miR-150*, miR-126, miR-125b, miR-103, miR-572, miR-494, miR-923, miR-130a, miR-213, miR-17, miR-142*, miR-206, miR-220, miR-221*, miR-222*, miR-182, miR-199a, let7, miR-424, miR-10a, miR-7, miR-126, miR-218	[345, 346, 358, 557, 558, 563–573]
MM	miR-21, miR-106b~25 cluster, miR-181a/b*, miR-20a, miR-19a, miR-19b, miR-93, miR-25, miR-92a, miR-19a, miR-19b, miR-32, miR-1, miR-133a, miR-193b~365,	let-7b, let-7-1, let-7c, miR-29a, and miR-29b, miR-328, miR-15a/16, miR-192~194~215, miR-181a/b*	[345, 574–579]
DLBCL	miR-155, miR-124a miR-125b*, miR-143, miR-451, miR-145, miR-10b, miR-34a, miR-100, miR-9, miR-21, miR-17~92, miR-128a, miR-106a/b, miR-425, miR-130b, miR-181b*	miR-27a/b, miR-29a/b/c; miR-142, miR-150, miR-125b*, miR-101, miR-28, miR-16, miR-189, miR-363, miR-223, miR-584, miR-361, miR-768, miR-625, miR-495, miR-181a*, miR-189, miR-363, miR-595, miR-663	[533, 564, 580–585]
C-ALCL	miR-155, miR-27b, miR-30c, miR-29b		[586]
ALK+-ALCL	miR-886-3p, miR-17, miR-18a, miR-20a, miR-363, miR-106a, miR-20a, miR-20b, miR-135b	miR-146a, miR-101, miR-29b, miR-26a, miR-29c, miR-29a, miR-22, miR-150, miR-125b	[587, 588]
ALK−-ALCL	miR-155	miR-101	[587]
cHL	miR-17~92 cluster, miR-16, miR-21, miR-24, miR27a, miR-124a, miR-134, miR-138, miR-155, miR-147, miR-182, miR-185, miR-198, miR-216, miR-220, miR-302a/b/c, miR-325	miR-23b, miR-30b, miR-31, miR-96, miR-126, miR-128a/b, miR-135a, miR-183, miR-204, miR-205, miR-335, miR-150	[584, 589, 590]
MCL	miR-124a, miR-155, miR-182, miR-183, miR-328, miR-326, miR-302c, miR-345, miR-373, miR-210, miR-617, miR-370, miR-654, miR-106b, miR-93, miR-25, miR-200c, miR-363, miR-181c, miR-654, miR-768	miR-29a/b/c, miR-142, miR-150, miR-15a/b, miR-31, miR-148a, miR-27b, miR-126	[564, 583, 591]
FL	miR-9, miR-20a/b, miR-301, miR-213, miR-330, miR-106a, miR-338, miR-155, miR-210, miR-138, miR-193a, miR-345, miR-513b, miR-574, miR-584, miR-663, miR-1287, miR-1295, miR-1471	miR-30a, miR-33a, miR-106a, miR-141, miR-202, miR-205, miR-222, miR-301b, miR-320, miR-149, miR-139, miR-431, miR-570	[135, 564, 582]

Abbreviations: ALK: anaplastic lymphoma kinase; ALCL: anaplastic large cell lymphoma; C-ALCL: cutaneous large cell lymphoma; cHL: classical Hodgkin's lymphoma; DLBCL: diffuse large B-cell lymphoma; FL: follicular lymphoma; MCL: mantle cell lymphoma.

*Variation in expression, dependent on the tumor grade.